The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 45 | — | 20.1x | Near average | |
Growth | 87 | 3118.1% | 5.6% | Above average | |
Quality | 45 | -19.5% | 7.6% | Near average | |
Safety | 69 | 0.6x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
IDEAYA Biosciences, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy IDEAYA Biosciences, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The data showed remarkable stability in the average price target at 58.67 dollars, despite 7 new analysts initiating coverage on the stock over the past 30 days, bringing the total number of analysts to 13. This strong consensus, along with a narrow gap between the low (53 dollars) and high (65 dollars) targets, reflects a decrease in uncertainty and high confidence in the stock's fair value, especially with the current price (28.4 dollars) remaining far from these targets.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.